According to the literature, the major antipneumocystic activity of this agent for PCP is derived from sulfamethoxazole (13) and the trimethoprim component is a very poor inhibitor of P. jirovecii DHFR (dihydrofolate reductase) (14). The gene discussed is DHFR; the disease is pneumocystosis.